文献速递血栓与止血

Denecimig(Mim8)每两周一次预防治疗血友病A的26周FRONTIER4结果

Denecimig (Mim8) prophylaxis once every 2 weeks for hemophilia A with or without inhibitors: 26-week results from FRONTIER4.
PubMed 文献 · Blood Adv · 2026-01-01

估计平均年化出血率为0.38次/患者年,83.8%患者零治疗出血。Denecimig每两周一次耐受良好,无安全性担忧。

要点

  • Denecimig每两周一次预防治疗血友病A(伴或不伴抑制物)耐受良好,无导致永久停药或致死的不良事件。
  • 估计平均年化出血率为0.38次/患者年,83.8%患者零治疗出血。
  • Denecimig血浆浓度稳定至第26周,2例报告14次注射部位反应。

核心结论

  • Denecimig每两周一次皮下预防治疗血友病A(伴或不伴抑制物)耐受良好,治疗出血少,无安全性担忧。

研究设计与样本

  • FRONTIER4为开放标签扩展研究,本文报告接受Denecimig每两周一次治疗26周患者的中期分析。

主要发现

  • 无TEAEs导致永久停用Denecimig,无致死性TEAEs;2例报告14次注射部位反应。
  • Denecimig血浆浓度稳定至第26周;估计平均年化出血率为0.38次/患者年,83.8%患者零治疗出血。

关键数值与推荐

  • 主要终点为治疗中出现的不良事件数量;次要终点包括注射部位反应、抗Denecimig抗体、Denecimig血浆浓度和治疗出血次数。
  • 估计平均年化出血率为0.38次/患者年;83.8%患者零治疗出血。

临床怎么用

  • Denecimig每两周一次皮下预防治疗可作为血友病A(伴或不伴抑制物)患者的一种耐受良好且出血控制良好的选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Denecimig (Mim8) is a next-generation, activated factor VIII mimetic, fully human bispecific immunoglobulin G4 antibody in development for subcutaneous prophylaxis in bleeding episodes, for patients with hemophilia A (HA) with/without inhibitors. FRONTIER4 is an open-label extension study to assess the safety and efficacy of denecimig. Here we present an interim analysis of patients receiving denecimig once every 2 weeks (Q2W) in FRONTIER4. Patients with HA aged ≥12 years who had participated in the denecimig phase 2 study and ≥12 weeks of its extension and entered arm 1 of the FRONTIER4 phase 3 study received denecimig Q2W for 26 weeks using a tiered dosing approach according to body weight range. The primary end point was the number of treatment-emergent adverse events (TEAEs); secondary end points included injection site reactions, occurrence of anti-denecimig antibodies, denecimig plasma concentrations, and number of treated bleeds. Thirty-seven patients were enrolled who received denecimig for a mean of 1.73 years in the phase 2 study. Sixty TEAEs were reported in 20 patients. Most TEAEs were mild/moderate in severity (98.3%), unlikely to be related to denecimig (75.0%), and resolved during the time frame of this analysis (90.0%). No TEAEs led to permanent discontinuation of denecimig, and none were fatal. Two patients reported 14 injection site reactions. Denecimig plasma concentrations were stable through week 26. The estimated mean annualized bleeding rate was 0.38 bleeds per patient year. Most patients experienced zero treated bleeds (83.8%). In summary, denecimig administered Q2W was well tolerated, with few patients experiencing treated bleeds and no safety concerns. This trial was registered at www.clinicaltrials.gov as NCT05685238.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Matsushita T, Banchev A, Bovet J, et al. Denecimig (Mim8) prophylaxis once every 2 weeks for hemophilia A with or without inhibitors: 26-week results from FRONTIER4. Blood Adv. 2026. PMID: 42469164. doi:10.1182/bloodadvances.2025019095

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。